ABCL635 Updated Nov 9
The next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
- Phase 2 data showed an 83% reduction in moderate-to-severe hot flash frequency versus 33% on placebo after a single dose, which the company describes as best-in-class.
- ABCL635 offers a differentiated monthly injectable dosing regimen versus daily oral pills (Veozah, Lynkuet), potentially improving compliance and convenience.
- The company raised $200M in an oversubscribed offering after Phase 2 data, providing a strong cash runway to fund Phase 3 development.
- ABCL635 faces entrenched oral competitors already on the market: Astellas' Veozah (fezolinetant) and Bayer's Lynkuet (elinzanetant), both daily pills approved for the same indication.
- As an injectable antibody, ABCL635 may face payer and patient adoption hurdles versus convenient daily oral pills, even with monthly dosing.
- The company is still pre-revenue on its own pipeline and posted a Q3 2026 operating loss of $40.8M, requiring continued capital raises beyond the $200M oversubscribed offering.